Indeed, the so called “double” or “triple hit lymphomas”, a subgroup of cases with particularly poor prognosis and previously largely included within DLBCL, are now regarded a distinct entity (“High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements”) separate from the “DLBCL, not otherwise specified (NOS)” as expressed in the 2017 WHO classification (24, 31, 39, 41–43). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.